IRIS Registry: Intelligent Research in Sight Registry

PROCEDURE

Ophthalmology

A registry of ophthalmic ambulatory encounters which captures essential data elements for continuous quality improvement efforts, enhanced patient care outcomes, and pay for performance programs.

Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation

Time frame: Up to 5 years

This measure is to be reported a minimum of once per reporting period for patients seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with primary open-angle glaucoma (in either one or both eyes) will submit this measure.

Age-Related Macular Degeneration (AMD): Dilated Macular Examination

Time frame: Up to 5 years

This measure is to be reported a minimum of once per reporting period for patients, aged 50 years and older, seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with age-related macular degeneration (in either one or both eyes) will submit this measure.

Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy

Time frame: Up to 5 years

Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months.

Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care

Time frame: Up to 5 years

Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the on-going care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months.

Preventive Care and Screening: Influenza Immunization

Time frame: Up to 5 years

Percentage of patients, aged 6 months and older, seen for a visit between October 1 and March 31 who received an influenza immunization, or who reported previous receipt of an influenza immunization.

Pneumonia Vaccination Status for Older Adults

Time frame: Up to 5 years

Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.

Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient

Time frame: Up to 5 years

Percentage of patients aged 18 through 75 years with a diagnosis of diabetes mellitus who had a dilated eye exam.

Documentation of Current Medications in the Medical Record

Time frame: Up to 5 years

Percentage of patients aged 18 years and older with a list of current medications (includes prescription, over-the-counter, herbals, vitamin/mineral/dietary nutritional supplements) documented by the provider, including drug name, dosage, frequency and route

Melanoma: Continuity of Care - Recall System

Time frame: Up to 5 years

This measure is to be reported a minimum of once per reporting period for melanoma patients seen during the reporting period. It is anticipated that clinicians providing care for patients with melanoma or a history of melanoma will submit this measure.

Melanoma: Coordination of Care

Time frame: Up to 5 years

This measure is to be reported at each visit occurring during the reporting period for melanoma patients seen during the reporting period. It is anticipated that clinicians providing care for patients with melanoma will submit this measure.

Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement

Time frame: Up to 5 years

Percentage of patients aged 50 years and older with a diagnosis of AMD and/or their caregiver(s) who were counseled within 12 months on the benefits and/or risks of the Age-Related Eye Disease Study (AREDS) formulation for preventing progression of AMD

Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% or Documentation of a Plan of Care

Time frame: Up to 5 years

Percentages of patients aged 18 years and older with a diagnosis of POAG whose glaucoma treatment has not failed (the most recent IOP was reduced by at least 15% from the pre-intervention level) or if the most recent IOP was not reduced by at least 15% from the pre-intervention level, a plan of care was documented within 12 months.

Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery

Time frame: Up to 5 years

Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and no significant ocular conditions impacting the visual outcome of surgery and had best-corrected visual acuity of 20/40 or better (distance or near) achieved within 90 days following the cataract surgery.

Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures

Time frame: Up to 5 years

Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and had any of a specified list of surgical procedures in the 30 days following cataract surgery which would indicate the occurrence of any of the following major complications; retained nuclear fragments, endophthalmitis, dislocated or wrong power intraocular lens, retinal detachment, or wound dehiscence.

Melanoma: Overutilization of Imaging Studies in Melanoma

Time frame: Up to 5 years

This measure is to be reported once per reporting period for patients with a current diagnosis of melanoma or a history of melanoma who are seen for an office visit during the reporting period. This measure is intended to reflect the quality of services provided for the primary management of patients with melanoma who have an office visit during the reporting period.

Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

Time frame: Up to 5 years

Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months and who received cessation counseling intervention if identified as a tobacco user.

Controlling High Blood Pressure

Time frame: Up to 5 years

Percentage of patients 18 through 85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (\< 140/90 mmHg) during the measurement period

Use of High-Risk Medications in the Elderly

Time frame: Up to 5 years

Percentage of patients aged 66 years and older who were ordered high-risk medications. Two rates are reported: 1. Percentage of patients who were ordered at least one high-risk medication. 2. Percentage of patients who were ordered at least two different high-risk medications.

Biopsy Follow-Up

Time frame: Up to 5 years

Percentage of patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient by the performing physician

Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery

Time frame: Up to 5 years

Percentage of patients aged 18 years and older in sample who had cataract surgery and had improvement in visual function achieved within 90 days following the cataract surgery, based on completing a pre-operative and postoperative visual function survey.

Patient Satisfaction within 90 Days Following Cataract Surgery

Time frame: Up to 5 years

Percentage of patients aged 18 years and older in sample who had cataract surgery and were satisfied with their care within 90 days following the cataract surgery, based on completion of the Consumer Assessment of Healthcare Providers and Systems Surgical Care Survey.

Falls: Screening for Future Fall Risk

Time frame: Up to 5 years

Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period.

Closing the Referral Loop: Receipt of Specialist Report

Time frame: Up to 5 years

Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred.

Adult Primary Rhegmatogenous Retinal Detachment Repair Success Rate

Time frame: Up to 5 years

Percentage of surgeries for primary rhegmatogenous retinal detachment where the retina remains attached after only one surgery

Adult Primary Rhegmatogenous Retinal Detachment Surgery Success Rate

Time frame: Up to 5 years

Percentage of retinal detachment cases achieving flat retinas six months post surgery

Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule requiring unplanned vitrectomy)

Time frame: Up to 5 years

Rupture of the posterior capsule during anterior segment surgery requiring vitrectomy

Cataract Surgery: Difference Between Planned and Final Refraction

Time frame: Up to 5 years

Percentage of patients who achieve planned refraction within +-1,0 D

Tobacco Use and Help with Quitting Among Adolescents

Time frame: Up to 5 years

The percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco user.

Corneal Graft: 20/40 or Better Visual Acuity within 90 Days following Corneal Graft Surgery

Time frame: Up to 5 years

Percentage of corneal graft surgery patients with a visual acuity of 20/40 or greater at 90 days after surgery

Open-Angle Glaucoma: Intraocular Pressure Reduction

Time frame: Up to 5 years

Percentage of glaucoma patient visits where their IOP was below a threshold level based on the severity of their diagnosis

Open-Angle Glaucoma: Visual Field Progression

Time frame: Up to 5 years

Percentage of eyes, in patients with a diagnosis of glaucoma, with a mean deviation loss of more than 3 decibels from their baseline value

Open-Angle Glaucoma: Intraocular Pressure Reduction Following Laser Trabeculoplasty

Time frame: Up to 5 years

Percentage of patients underwent laser trabeculoplasty who had IOP reduced by 20% from their pretreatment level

Acquired Involutional Ptosis: Improvement of Marginal Reflex Distance within 90 Days Following Surgery for Acquired Involutional Ptosis

Time frame: Up to 5 years

Percentage of surgical ptosis patients with an improvement of marginal reflex distance postoperatively

Acquired Involutional Entropion: Normalization of Eyelid Position within 90 Days Following Surgery for Acquired Involutional Entropion

Time frame: Up to 5 years

Percentage of surgical entropion patients with a postoperative normalized lid position

Amblyopia: Improvement of Corrected Interocular Visual Acuity Difference to 2 or fewer Lines

Time frame: Up to 5 years

Percentage of newly diagnosed amblyopic patients with a corrected interocular VA difference of 2 or fewer lines (\< 0.23 logMAR) within 6 months of first diagnosis

Surgical Esotropia: Patients with Postoperative Alignment of 15 prism diopters or less

Time frame: Up to 5 years

Percentage of surgical esotropia patients with a postoperative alignment of 15 prism diopters or less

Diabetic Retinopathy: Dilated Eye Exam

Time frame: Up to 5 years

Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months

Exudative Age-Related Macular Degeneration: Loss of Visual Acuity

Time frame: Up to 5 years

Percentage of patients with a diagnosis of nonexudative age-related macular degeneration and taking AREDS supplements with of loss of less than 0.3 logMar of visual acuity within the past 12 months

Nonexudative Age-Related Macular Degeneration: Loss of Visual Acuity

Time frame: Up to 5 years

Percentage of patients with nonexudative age-related macular degeneration progressing to exudative age-related macular degeneration over the past 12 months

Diabetic Macular Edema: Loss of Visual Acuity

Time frame: Up to 5 years

Percentage of patients with a diagnosis of diabetic macular edema with of loss of less than 0.3 logMar of visual acuity within the past 12 months

Rhegmatogenous Retinal Detachment Surgery: Visual acuity improvement within 90 days of surgery

Time frame: Up to 5 years

Percentage of patients who underwent rhegmatogenous retinal detachment surgery and achieved an improvement in their visual acuity from their preoperative level within 90 days of surgery in the treated eye.

Rhegmatogenous Retinal Detachment Surgery: Return to the operating room within 90 days of surgery

Time frame: Up to 5 years

Percentage of patients who underwent rhegmatogenous retinal detachment surgery and had a return to the operating room within 90 days

Acute Anterior Uveitis: Post-treatment visual acuity

Time frame: Up to 5 years

Percentage of acute anterior uveitis patients with a post-treatment best corrected visual acuity of 20/40 or greater OR patients whose visual acuity had returned to their baseline value prior to onset of uveitis

Acute Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells

Time frame: Up to 5 years

Percentage of patients with acute anterior uveitis post-treatment with Grade 0 anterior chamber cells

Chronic Anterior Uveitis: Post-treatment visual acuity

Time frame: Up to 5 years

Percentage of chronic anterior uveitis patients with a post-treatment best corrected visual acuity of 20/40 or greater OR patients whose visual acuity had returned to their baseline value prior to onset of uveitis

Chronic Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells

Time frame: Up to 5 years

Percentage of patients with chronic anterior uveitis post-treatment with Grade 0 anterior chamber cells

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.